296 related articles for article (PubMed ID: 22743037)
21. Anti-HIV-1 ADCC and HIV-1 Env Can Be Partners in Reducing Latent HIV Reservoir.
Suryawanshi P; Bagul R; Shete A; Thakar M
Front Immunol; 2021; 12():663919. PubMed ID: 33995393
[TBL] [Abstract][Full Text] [Related]
22. Exosomal Tat protein activates latent HIV-1 in primary, resting CD4+ T lymphocytes.
Tang X; Lu H; Dooner M; Chapman S; Quesenberry PJ; Ramratnam B
JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618654
[TBL] [Abstract][Full Text] [Related]
23. From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication.
Shan L; Siliciano RF
Bioessays; 2013 Jun; 35(6):544-52. PubMed ID: 23613347
[TBL] [Abstract][Full Text] [Related]
24. Select host restriction factors are associated with HIV persistence during antiretroviral therapy.
Abdel-Mohsen M; Wang C; Strain MC; Lada SM; Deng X; Cockerham LR; Pilcher CD; Hecht FM; Liegler T; Richman DD; Deeks SG; Pillai SK
AIDS; 2015 Feb; 29(4):411-20. PubMed ID: 25602681
[TBL] [Abstract][Full Text] [Related]
25. TLR1/2 Agonist Enhances Reversal of HIV-1 Latency and Promotes NK Cell-Induced Suppression of HIV-1-Infected Autologous CD4
Duan S; Xu X; Wang J; Huang L; Peng J; Yu T; Zhou Y; Cheng K; Liu S
J Virol; 2021 Aug; 95(17):e0081621. PubMed ID: 34133900
[TBL] [Abstract][Full Text] [Related]
26. Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: implications for the development of therapeutic strategies.
Chun TW; Justement JS; Moir S; Hallahan CW; Ehler LA; Liu S; McLaughlin M; Dybul M; Mican JM; Fauci AS
Proc Natl Acad Sci U S A; 2001 Jan; 98(1):253-8. PubMed ID: 11136258
[TBL] [Abstract][Full Text] [Related]
27. Latency reversal plus natural killer cells diminish HIV reservoir in vivo.
Kim JT; Zhang TH; Carmona C; Lee B; Seet CS; Kostelny M; Shah N; Chen H; Farrell K; Soliman MSA; Dimapasoc M; Sinani M; Blanco KYR; Bojorquez D; Jiang H; Shi Y; Du Y; Komarova NL; Wodarz D; Wender PA; Marsden MD; Sun R; Zack JA
Nat Commun; 2022 Jan; 13(1):121. PubMed ID: 35013215
[TBL] [Abstract][Full Text] [Related]
28. HIV persistence: chemokines and their signalling pathways.
Evans VA; Khoury G; Saleh S; Cameron PU; Lewin SR
Cytokine Growth Factor Rev; 2012; 23(4-5):151-7. PubMed ID: 22749173
[TBL] [Abstract][Full Text] [Related]
29. The role of latency reversal agents in the cure of HIV: A review of current data.
Bashiri K; Rezaei N; Nasi M; Cossarizza A
Immunol Lett; 2018 Apr; 196():135-139. PubMed ID: 29427743
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-7 promotes HIV persistence during antiretroviral therapy.
Vandergeeten C; Fromentin R; DaFonseca S; Lawani MB; Sereti I; Lederman MM; Ramgopal M; Routy JP; Sékaly RP; Chomont N
Blood; 2013 May; 121(21):4321-9. PubMed ID: 23589672
[TBL] [Abstract][Full Text] [Related]
31. Curing HIV: Pharmacologic approaches to target HIV-1 latency.
Choudhary SK; Margolis DM
Annu Rev Pharmacol Toxicol; 2011; 51():397-418. PubMed ID: 21210747
[TBL] [Abstract][Full Text] [Related]
32. What can we do to reduce the viral reservoir in HIV-1-infected individuals?
Pohlmeyer CW; Walker-Sperling VE; Blankson JN
Future Microbiol; 2016 Jul; 11():839-42. PubMed ID: 27416850
[No Abstract] [Full Text] [Related]
33. Peering into the HIV reservoir.
García M; Buzón MJ; Benito JM; Rallón N
Rev Med Virol; 2018 Jul; 28(4):e1981. PubMed ID: 29744964
[TBL] [Abstract][Full Text] [Related]
34. Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors.
Gavegnano C; Brehm JH; Dupuy FP; Talla A; Ribeiro SP; Kulpa DA; Cameron C; Santos S; Hurwitz SJ; Marconi VC; Routy JP; Sabbagh L; Schinazi RF; Sékaly RP
PLoS Pathog; 2017 Dec; 13(12):e1006740. PubMed ID: 29267399
[TBL] [Abstract][Full Text] [Related]
35. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection.
Chun TW; Engel D; Berrey MM; Shea T; Corey L; Fauci AS
Proc Natl Acad Sci U S A; 1998 Jul; 95(15):8869-73. PubMed ID: 9671771
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological Modulation of the Wnt/β-Catenin Pathway Inhibits Proliferation and Promotes Differentiation of Long-Lived Memory CD4
Mavigner M; Zanoni M; Tharp GK; Habib J; Mattingly CR; Lichterfeld M; Nega MT; Vanderford TH; Bosinger SE; Chahroudi A
J Virol; 2019 Dec; 94(1):. PubMed ID: 31619550
[TBL] [Abstract][Full Text] [Related]
37. Reservoirs of HIV replication after successful combined antiretroviral treatment.
Belmonte L; Baré P; de Bracco MM; Ruibal-Ares BH
Curr Med Chem; 2003 Feb; 10(4):303-12. PubMed ID: 12570703
[TBL] [Abstract][Full Text] [Related]
38. Autologous neutralizing antibody to human immunodeficiency virus-1 and replication-competent virus recovered from CD4+ T-cell reservoirs in pediatric HIV-1-infected patients on HAART.
Ching N; Nielsen-Saines KA; Deville JG; Wei LS; Garratty E; Bryson YJ
AIDS Res Hum Retroviruses; 2010 May; 26(5):585-91. PubMed ID: 20455762
[TBL] [Abstract][Full Text] [Related]
39. A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs.
Lassen KG; Hebbeler AM; Bhattacharyya D; Lobritz MA; Greene WC
PLoS One; 2012; 7(1):e30176. PubMed ID: 22291913
[TBL] [Abstract][Full Text] [Related]
40. A reservoir for HIV in patients on combination antiretroviral therapy.
Siliciano RF
Hopkins HIV Rep; 1998 Jan; 10(1):1, 5-6, 11. PubMed ID: 11365130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
